Cladribine
In the US, Cladribine (cladribine systemic) is a member of the drug class antimetabolites and is used to treat Hairy Cell Leukemia and Multiple Sclerosis.
US matches:
UK matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01BB04
CAS registry number (Chemical Abstracts Service)
0004291-63-8
Chemical Formula
C10-H12-Cl-N5-O3
Molecular Weight
285
Therapeutic Category
Cytostatic agent: Antimetabolite
Chemical Name
2-Chloro-2'-deoxyadenosine
Foreign Names
- Cladribinum (Latin)
- Cladribin (German)
- Cladribine (French)
- Cladribina (Spanish)
Generic Names
- Cladribine (OS: BAN, DCF, USAN, JAN)
- CdA (IS)
- Chlorodeoxyadenosine (IS)
- RWJ 26251 (IS)
- RWJ 26251-000 (IS)
- Cladribine (PH: BP 2016, Ph. Eur. 8, USP 38)
- Cladribinum (PH: Ph. Eur. 8)
Brand Names
- Ai Bo Ding
Hisun Pfizer, China - Biodribin
Inst. Biotechn. i Antybiotykow, Poland - Cladribine Agila
Agila, Netherlands; Agila Specialties, Poland - Cladribine Bedford
Bedford, United States - Hemobine
Dosa, Argentina - Intocel
Sidus, Argentina - Leustat
Janssen Cilag, Argentina; Janssen-Cilag, Egypt; Janssen-Cilag, United Kingdom; Janssen-Cilag, Lebanon - Leustatin
Cilag, Hong Kong; Janssen, Australia; Janssen, Brazil; Janssen, Finland; Janssen, Lebanon; Janssen, Norway; Janssen, New Zealand; Janssen, Taiwan; Janssen, South Africa; Janssen Cilag, Netherlands; Janssen Pharmaceutical, Japan; Janssen-Cilag, Belgium; Janssen-Cilag, Switzerland; Janssen-Cilag, Germany; Janssen-Cilag, Greece; Janssen-Cilag, Italy; Janssen-Cilag, Portugal - Leustatine
Janssen-Cilag, France - Litak
Inter Farmacia Italia, Italy; Key Oncologics, South Africa; Lipomed, Austria; Lipomed, Belgium; Lipomed, Switzerland; Lipomed, Czech Republic; Lipomed, Germany; Lipomed, Denmark; Lipomed, Spain; Lipomed, France; Lipomed, United Kingdom; Lipomed, Hungary; Lipomed, Israel; Lipomed, Lithuania; Lipomed, Netherlands; Lipomed, Norway; Lipomed, Poland; Lipomed, Portugal; Lipomed, Romania; Lipomed, Serbia; Lipomed, Taiwan; Lipomed GmbH, Greece; Medifront, Finland; Medis Adria, Croatia (Hrvatska); Orphan, Australia - Movectro
Merck Serono, Australia
Glossary
Term | Definition |
---|---|
BAN | British Approved Name |
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
JAN | Japanese Accepted Name |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.